Operational Update Released: Market participants have been actively analyzing the latest operational update from the company, focusing on its asset portfolio and board developments. Some observers highlight the strong fundamentals and detailed reporting as key positives. Others note concerns around share overhang from prior directors and recent management changes.
Price Movement Observed: The stock saw a notable 17% gain following the announcement, prompting discussions on its potential trajectory. Commentators describe the update as detailed and compelling, with some expressing interest in long-term holding strategies. Targets mentioned in conversations reach as high as 50p, reflecting enthusiasm tempered by the need for additional financing.
Broader Context Considered: Discussions emphasize the company's back story and asset quality amid a quiet overall chatter on the ticker. While some view it as a compelling opportunity, caution prevails regarding execution risks. The overall tone remains one of measured interest in the evolving situation.
Note: This discussion summary was generated from an AI condensation of post data.
Neo Insider Trading Activity
Neo insiders have traded $NEO stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $NEO stock by insiders over the last 6 months:
- WARREN STONE (Pres & Chief Operating Officer) sold 22,128 shares for an estimated $276,681
- LYNN A. TETRAULT has made 0 purchases and 2 sales selling 10,614 shares for an estimated $118,823.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Neo Revenue
Neo had revenues of $186.7M in Q1 2026. This is an increase of 11.09% from the same period in the prior year.
You can track NEO financials on Quiver Quantitative's NEO stock page.
You can access data on NEO stock through the Quiver Quantitative API.
Neo Hedge Fund Activity
We have seen 103 institutional investors add shares of Neo stock to their portfolio, and 111 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST TRUST ADVISORS LP added 6,162,371 shares (+inf%) to their portfolio in Q1 2026, for an estimated $45,724,792
- MILLENNIUM MANAGEMENT LLC removed 2,981,652 shares (-57.3%) from their portfolio in Q1 2026, for an estimated $22,123,857
- BANK OF AMERICA CORP /DE/ added 1,706,472 shares (+126.6%) to their portfolio in Q1 2026, for an estimated $12,662,022
- SAMLYN CAPITAL, LLC added 1,169,128 shares (+84.2%) to their portfolio in Q1 2026, for an estimated $8,674,929
- CITADEL ADVISORS LLC removed 1,043,726 shares (-79.8%) from their portfolio in Q1 2026, for an estimated $7,744,446
- TREXQUANT INVESTMENT LP removed 848,866 shares (-95.9%) from their portfolio in Q1 2026, for an estimated $6,298,585
- GRANITE INVESTMENT PARTNERS, LLC added 752,478 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,583,386
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Neo Government Contracts
We have seen $5,520,559 of award payments to $NEO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- STX SPECIALIZED REFERENCE LABORATORY TESTING: $2,787,350
- REFERENCE LAB TESTING FOR VACCHCS: $643,694
- CALL ORDER FOR LAB DIAGNOSTIC TESTING: $401,779
- TASK ORDER FOR SERVICES ORDERING PERIOD 5 OFF-SITE ANATOMIC PATHOLOGY LAB SERVICES VACCHCS: $325,000
- IMMUNOHISTOCHEMISTRY (IHC) TESTING: $150,010
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Neo Analyst Ratings
Wall Street analysts have issued reports on $NEO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Benchmark issued a "Buy" rating on 04/29/2026
- Needham issued a "Buy" rating on 02/17/2026
To track analyst ratings and price targets for Neo, check out Quiver Quantitative's $NEO forecast page.
Neo Price Targets
Multiple analysts have issued price targets for $NEO recently. We have seen 5 analysts offer price targets for $NEO in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Bruce Jackson from Benchmark set a target price of $11.0 on 04/29/2026
- Puneet Souda from Leerink Partners set a target price of $25.0 on 04/29/2026
- Dan Brennan from TD Cowen set a target price of $14.0 on 04/29/2026
- David Westenberg from Piper Sandler set a target price of $13.0 on 02/24/2026
- Mike Matson from Needham set a target price of $15.0 on 02/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
